剖宫产术后基于体重与固定剂量依诺肝素预防血栓的随机对照试验
该随机对照试验纳入符合剖宫产术后依诺肝素血栓预防标准的个体,比较固定剂量与基于体重给药达到预防性抗Xa水平的效果。基于体重组达预防性抗Xa水平的比例高于固定剂量组(主要分析66% vs 44%,RR 1.49,95%CI 1.10-2.02),结论为基于体重给药更有效。
要点
- 基于体重依诺肝素组达预防性抗Xa峰水平的比例高于固定剂量组(66% vs 44%,RR 1.49)。
- 固定剂量组亚预防性抗Xa水平更常见,超预防性水平两组无显著差异。
- 门诊随访时基于体重组达预防性抗Xa峰比例高于固定剂量组(52% vs 15%,RR 3.41)。
核心结论
- 剖宫产术后基于体重依诺肝素给药在达到预防性抗Xa峰水平方面比固定剂量更有效。
研究设计与样本
- 随机对照试验,纳入符合机构剖宫产术后依诺肝素血栓预防标准的个体,随机分配至固定剂量组(BMI低于40者40 mg每日一次;BMI 40或以上者40 mg每12小时一次)或基于体重组(0.5 mg/kg每12小时一次),依诺肝素住院期间开始并出院后继续14天,试验为非盲法。
- 计划每组样本量121例,在入组50%时中期分析因有效性提前终止;主要分析采用意向性治疗原则,缺失结局采用最差情况填补,次要分析为完整病例分析。
- 2020年6月至2021年11月,74例随机至基于体重依诺肝素组,72例随机至固定剂量依诺肝素组。
主要发现
- 主要分析中基于体重组达预防性抗Xa水平(0.2-0.6国际单位/mL,至少第三次依诺肝素剂量后4-6小时稳态峰浓度)的比例为49/74(66%),固定剂量组为32/72(44%),RR 1.49,95%CI 1.10-2.02。
- 次要分析中基于体重组达预防性抗Xa水平的比例为49/60(82%),固定剂量组为32/57(56%),RR 1.45,95%CI 1.12-1.88。
- 固定剂量组亚预防性抗Xa水平更常见;超预防性抗Xa水平两组无显著差异。
- 门诊术后随访时,基于体重组达预防性抗Xa峰水平的比例为52%(15/29),固定剂量组为15%(5/33),RR 3.41,95%CI 1.42-8.24。
- 两组均无静脉血栓栓塞症(VTE);伤口并发症基于体重组5例(7%),固定剂量组1例(1%),RR 4.86,95%CI 0.58-40.63。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate fixed compared with weight-based enoxaparin dosing to achieve prophylactic anti-Xa levels after cesarean delivery. METHODS: Individuals meeting institutional criteria for enoxaparin thromboprophylaxis after cesarean delivery were randomly allocated to fixed (40 mg daily for body mass index [BMI, calculated as weight in kilograms divided by height in meters squared] lower than 40; 40 mg every 12 hours for BMI 40 or higher) or weight-based (0.5 mg/kg every 12 hours) enoxaparin dosing. Enoxaparin was initiated during inpatient hospitalization and continued at discharge for 14 days. Those with contraindication to anticoagulation, plan for therapeutic anticoagulation, or known renal impairment were excluded. The trial was unmasked. The primary outcome was prophylactic (0.2-0.6 international units/mL) peak anti-Xa level 4-6 hours after at least the third enoxaparin dose (at steady state). Secondary outcomes included subprophylactic and supraprophylactic peaks, outpatient peak, and venous thromboembolism (VTE) and wound complications in the first 6 weeks postpartum. Sample size of 121 per group was planned. At interim analysis with 50% enrollment, the trial was stopped early for efficacy. Primary analyses followed intention-to-treat principle with worst-case imputation for missing outcomes. Secondary analyses were complete case. RESULTS: From June 2020 to November 2021, 74 individuals were randomized to weight-based enoxaparin and 72 to fixed-dose enoxaparin. Those who received weight-based dosing were more likely to achieve prophylactic anti-Xa levels than those who received fixed dosing in primary analysis (49/74 [66%] vs 32/72 [44%], relative risk [RR] 1.49, 95% CI 1.10-2.02) and secondary analysis (49/60 [82%] vs 32/57 [56%], RR 1.45, 95% CI 1.12-1.88). Subprophylactic levels occurred more frequently with fixed dosing; supraprophylactic levels did not differ significantly by dosing. At the outpatient postoperative visit, 52% of participants (15/29) with weight-based dosing compared with 15% (5/33) with fixed dosing achieved prophylactic peak anti-Xa level (RR 3.41, 95% CI 1.42-8.24). There were no VTEs in either group. Wound complications occurred in five individuals (7%) with weight-based enoxaparin dosing compared with one individual (1%) with fixed enoxaparin dosing (RR 4.86, 95% 0.58-40.63). CONCLUSION: Weight-based dosing was more effective than fixed enoxaparin dosing in achieving prophylactic peak anti-Xa levels after cesarean delivery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04305756.
引用
- Bruno AM, Allshouse AA, Campbell HM, et al. Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2022. PMID: 36075079. doi:10.1097/AOG.0000000000004937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。